Last updated: November 8, 2026
PROLENSA is Bausch + Lomb’s bromfenac ophthalmic solution 0.07% for postoperative inflammation and ocular pain after cataract surgery. Its commercial value rests on once-daily dosing, established surgeon adoption, and the large U.S. cataract-procedure market. Its main constraints are therapeutic substitution, payer pressure, generic bromfenac competition, and the absence of publicly reported product-level revenue.
Bausch + Lomb does not separately disclose PROLENSA sales. Public filings report results by business segment rather than by individual ophthalmic brand, so PROLENSA’s financial trajectory must be inferred from product maturity, market access, procedure volumes, and generic competition rather than audited brand revenue.
What is PROLENSA and how is it used?
PROLENSA contains bromfenac sodium, a nonsteroidal anti-inflammatory drug, or NSAID, formulated as a 0.07% ophthalmic solution.
| Item |
Details |
| Brand |
PROLENSA |
| Active ingredient |
Bromfenac sodium |
| Strength |
0.07% ophthalmic solution |
| FDA application |
NDA 204091 |
| U.S. approval |
October 2013 |
| Sponsor |
Bausch + Lomb Incorporated |
| Indication |
Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery |
| Recommended dosing |
One drop once daily, beginning one day before surgery, continued on the day of surgery and for 14 days after surgery |
| Primary channel |
Ophthalmology and ambulatory cataract surgery |
| Dosage form |
Multidose topical ophthalmic solution |
The FDA-approved dosage is a commercial differentiator. Many competing ophthalmic NSAID products require dosing two to four times daily. PROLENSA’s once-daily schedule can reduce administration burden, although the benefit is limited when physicians and payers prioritize acquisition cost. (U.S. Food and Drug Administration [FDA], 2013)
How large is the market for PROLENSA?
The addressable market is the U.S. cataract-surgery postoperative anti-inflammatory market. Cataract surgery is one of the highest-volume procedures in the U.S., with procedure demand supported by population aging, Medicare coverage, and improved surgical throughput.
The commercial market has four principal segments:
- Branded ophthalmic NSAIDs, including PROLENSA, NEVANAC, ILEVRO, and BROMDAY.
- Generic ketorolac and diclofenac.
- Generic or authorized-generic bromfenac products.
- Combination or alternative delivery products, including intraocular inserts and compounded postoperative regimens.
PROLENSA competes primarily on convenience and surgeon familiarity rather than on a novel mechanism. Bromfenac inhibits cyclooxygenase-mediated prostaglandin synthesis, a mechanism shared by other ophthalmic NSAIDs.
What drives PROLENSA demand?
Demand is linked to:
- Annual cataract-procedure volume.
- Surgeon preference for once-daily NSAID dosing.
- Hospital and ambulatory surgery center formularies.
- Reimbursement and patient copay exposure.
- Use of branded postoperative drug bundles.
- Distributor and pharmacy inventory.
- Availability of generic bromfenac 0.07%.
- Shifts toward compounded or intraoperative alternatives.
Cataract volume is structurally favorable, but unit growth does not necessarily translate into brand revenue growth. Physicians can treat the same procedure with lower-priced generics, and many payers impose formulary restrictions on branded ophthalmic NSAIDs.
What is the financial trajectory of PROLENSA?
PROLENSA is best characterized as a mature branded ophthalmic product with declining pricing power rather than a growth-stage asset.
Bausch + Lomb reports product categories and operating segments, not individual brand revenue. Its public filings do not identify PROLENSA net sales, gross margin, prescription volume, or contribution profit. As a result, no reliable public revenue series exists for the brand.
Financial trajectory by phase
| Period |
Commercial phase |
Financial implication |
| 2013-2015 |
U.S. launch and physician adoption |
Revenue growth supported by new-product positioning and once-daily dosing |
| 2016-2019 |
Brand expansion and formulary development |
Growth increasingly dependent on reimbursement, samples, and contracting |
| 2020 |
Procedure disruption during COVID-19 |
Temporary pressure from postponed cataract surgeries |
| 2021-2022 |
Procedure recovery |
Volume recovery supported branded ophthalmic demand |
| 2023 onward |
Mature-brand phase |
Price pressure, generic substitution, and formulary management limit growth |
The key financial issue is not whether cataract surgery demand remains large. It does. The issue is how much of that demand converts into paid branded PROLENSA units rather than generic bromfenac, ketorolac, diclofenac, nepafenac, or lower-cost surgical protocols.
Bausch + Lomb’s ophthalmic pharmaceutical portfolio remains strategically important, but its corporate filings do not support a claim that PROLENSA is a material standalone driver of consolidated revenue. Brand-level exposure is likely meaningful within the surgical ophthalmology portfolio but small relative to the company’s total sales base.
How does PROLENSA compare with competing ophthalmic NSAIDs?
| Product |
Active ingredient |
Typical dosing burden |
Commercial position |
| PROLENSA |
Bromfenac 0.07% |
Once daily |
Branded convenience product |
| BROMDAY |
Bromfenac 0.09% |
Once daily |
Older bromfenac brand; limited current visibility |
| ILEVRO |
Nepafenac 0.3% |
Once daily |
Branded cataract NSAID competitor |
| NEVANAC |
Nepafenac 0.1% |
Three times daily |
Established branded product |
| ACULAR and generics |
Ketorolac tromethamine |
Often four times daily |
Lower-cost generic benchmark |
| Diclofenac generics |
Diclofenac sodium |
Multiple daily doses |
Low-cost substitution option |
| BROMFENAC generics |
Bromfenac |
Product-dependent |
Direct price competition |
PROLENSA’s strongest commercial advantage is dosing convenience against older generic NSAIDs. Its weakest position is price relative to generic ketorolac and diclofenac. ILEVRO provides the closest branded once-daily alternative, while NEVANAC competes through brand history and surgeon familiarity.
When does PROLENSA lose exclusivity?
PROLENSA’s market exclusivity is not controlled by a single date. It depends on several forms of protection:
- FDA regulatory exclusivity.
- Orange Book-listed patents.
- Patent-term adjustment or patent-term extension.
- Litigation settlements.
- FDA approval timing for ANDA applicants.
- Commercial decisions by generic manufacturers.
NDA 204091 was approved in 2013. The product’s five-year new-chemical-entity exclusivity period would have expired in 2018, assuming standard FDA treatment of the active ingredient. That period blocked submission of an ANDA relying on the NDA during the initial exclusivity window but did not create a long-term barrier to generic entry.
The more important protection is patent coverage. Publicly available product information identifies PROLENSA’s formulation and dosage regimen, but a reliable current determination of enforceable patent expiry requires reviewing the live FDA Orange Book listings, patent-term calculations, and any later delistings or litigation outcomes. Product-level revenue analysis should therefore treat PROLENSA as exposed to generic competition rather than as a fully protected branded asset.
What patents protect PROLENSA?
The commercial protection around PROLENSA is likely to center on formulation, concentration, dosing, and ophthalmic delivery rather than on the basic bromfenac molecule alone.
Potential protection categories include:
| Protection category |
Relevance to PROLENSA |
| Active-ingredient patents |
Limited value if bromfenac itself is off-patent |
| Ophthalmic formulation patents |
May cover concentration, excipients, pH, stability, or delivery characteristics |
| Method-of-use patents |
May cover treatment of postoperative inflammation or pain |
| Dosing patents |
May cover once-daily administration or specified perioperative timing |
| Manufacturing patents |
May protect preparation or stability processes |
| Regulatory exclusivity |
Expired five-year NCE period based on the 2013 approval date |
Formulation and method-of-use patents can delay or complicate generic entry, but they usually have less commercial durability than composition-of-matter patents. Generic applicants can challenge listed patents through Paragraph IV certifications or seek approval with labels that omit patented indications.
What Orange Book status does PROLENSA have?
PROLENSA’s Orange Book relevance depends on which patents remain listed against NDA 204091 and whether any listed claims cover the approved product, its formulation, or the labeled use. An Orange Book listing does not guarantee that a patent will survive litigation or block a design-around product.
For investment purposes, the practical question is whether an ANDA applicant can obtain approval with a Paragraph IV certification, a section viii statement omitting a patented use, or a non-infringing formulation. The answer determines whether generic entry occurs before the nominal patent expiry date.
Are there Paragraph IV challenges to PROLENSA?
A Paragraph IV challenge is the principal litigation route for a generic manufacturer seeking approval before expiration of an Orange Book-listed patent. The applicant asserts that the patent is invalid, unenforceable, or not infringed.
No publicly documented, high-profile Paragraph IV campaign against PROLENSA has established a broad market-wide launch date comparable to major oral drugs. That does not eliminate generic risk. Ophthalmic products can enter through ANDA approvals, patent settlements, authorized generics, or product-specific litigation that receives limited public attention.
The financial effect of a Paragraph IV challenge can begin before launch. It may trigger:
- Higher legal expenses.
- Greater contracting pressure from wholesalers and payers.
- Discounting by the brand manufacturer.
- Inventory reductions.
- Prescriber switching.
- Lower expected terminal value for the brand.
What generic entry risks exist for PROLENSA?
PROLENSA faces four generic-entry scenarios.
| Scenario |
Likely commercial effect |
| No approved direct generic |
Brand retains pricing and formulary leverage, but remains exposed to therapeutic substitution |
| One direct bromfenac 0.07% generic |
Moderate-to-severe price erosion and payer substitution |
| Multiple direct generics |
Rapid loss of unit share and substantial net-price decline |
| Generic entry plus branded alternative competition |
Accelerated erosion because physicians have several low-cost options |
Ophthalmic generics can face manufacturing and quality barriers, including sterility, container-closure integrity, drop-size consistency, preservative performance, particulate control, and stability. These barriers can reduce the number of immediate entrants. They do not provide durable protection if multiple manufacturers obtain approval.
A generic bromfenac product does not need to reproduce every commercial feature of PROLENSA to compete. FDA-approved sameness in the relevant active ingredient, dosage form, strength, route, and bioequivalence framework can support substitution or formulary displacement.
What FDA regulatory status does PROLENSA have?
PROLENSA is an FDA-approved prescription ophthalmic product under NDA 204091. Its approved indication is postoperative inflammation and ocular pain associated with cataract surgery.
Regulatory risk is relatively low compared with products requiring new clinical development. The major FDA-related commercial risks are:
- Labeling changes affecting warnings or administration.
- Manufacturing observations.
- Supply interruptions.
- Product complaints involving bottle performance or sterility.
- Generic ANDA approvals.
- Changes in reimbursement or Medicare treatment of postoperative medicines.
PROLENSA is not a biologic, so biosimilar risk does not apply. Its competitive risk comes from ANDA-approved generics and therapeutic alternatives, not from the abbreviated biosimilar pathway.
Which companies challenge PROLENSA commercially?
The competitive field includes Bausch + Lomb, Novartis through its ophthalmic portfolio, Sun Pharmaceutical Industries, and generic manufacturers supplying ketorolac, diclofenac, nepafenac, and bromfenac.
The most relevant competitive groups are:
Branded ophthalmology companies
Bausch + Lomb competes through its own surgical-pharmaceutical portfolio, distribution network, and relationships with cataract surgeons. Novartis has historically competed through NEVANAC and ILEVRO. Sun Pharma competes in ophthalmology through branded and specialty products, including bromfenac-related products in certain markets.
Generic manufacturers
Generic ophthalmic manufacturers can compete through lower acquisition cost and pharmacy substitution. Their commercial power increases when payers remove branded products from preferred tiers or when ambulatory surgery centers standardize postoperative regimens.
Surgical alternatives
Some surgeons use compounded drops, intraoperative NSAID or steroid delivery, or drug-delivery inserts. These approaches can reduce the number of postoperative prescriptions per procedure and weaken demand for branded topical products.
What licensing deals affect PROLENSA?
PROLENSA’s commercial history is associated with Bausch + Lomb’s ophthalmic platform and its acquisition of ISTA Pharmaceuticals in 2012. Bausch + Lomb acquired ISTA for approximately $500 million, bringing ISTA’s ophthalmic assets into Bausch + Lomb’s portfolio. PROLENSA was approved after the acquisition. (Valeant Pharmaceuticals International, 2012; FDA, 2013)
Public corporate filings do not identify a separate, current PROLENSA royalty stream or major third-party licensing arrangement that would materially change the product’s financial profile. The principal economic owner is Bausch + Lomb.
What patent litigation affects PROLENSA?
The litigation risk is primarily generic-entry litigation involving Orange Book-listed formulation or use patents. The absence of a widely reported landmark case does not mean the asset is litigation-free. Ophthalmic products often face narrower ANDA disputes than blockbuster systemic medicines, and commercial outcomes can be determined by settlement terms, licensing, authorized-generic arrangements, or launch-at-risk decisions.
For valuation, the important litigation variables are:
- Whether any listed patent remains unexpired.
- Whether the patent claims cover the commercial product or only a narrow formulation.
- Whether a generic applicant can use a section viii carve-out.
- Whether a settlement grants an agreed launch date.
- Whether Bausch + Lomb supplies or licenses an authorized generic.
- Whether manufacturing challenges delay commercial entry.
How strong is the PROLENSA patent estate?
PROLENSA’s patent estate is commercially moderate rather than exceptionally strong.
Its strengths are:
- A differentiated once-daily product profile.
- Formulation-specific protection may be harder to design around than a simple method-of-use claim.
- Sterile ophthalmic manufacturing creates technical barriers.
- Surgeon familiarity can preserve some demand after patent expiry.
Its weaknesses are:
- Bromfenac is an established active ingredient.
- The product has no long-term composition-of-matter exclusivity comparable to a newly discovered molecule.
- Multiple NSAID alternatives are available.
- Generic ophthalmic manufacturers can target the same cataract indication.
- Payers can substitute on price.
- The five-year NCE exclusivity period has expired.
What is the generic launch outlook for PROLENSA?
The most likely commercial outcome is gradual erosion followed by sharper decline if multiple direct bromfenac 0.07% generics reach the market.
A plausible launch sequence is:
- Initial generic approval with limited distribution.
- Payer and wholesaler testing.
- Broader substitution if the product receives favorable reimbursement.
- Brand discounting and contracting.
- Declining branded prescription share.
- Retention of a smaller premium segment among surgeons who value once-daily branded dosing or prefer established supply.
The impact would be less severe if direct generic penetration remains limited and physicians continue using branded postoperative protocols. It would be greater if a major payer or integrated surgery network adopts generic bromfenac as a preferred product.
What is the geographic coverage of PROLENSA?
The financial case is primarily U.S.-driven because the FDA approval, Orange Book framework, and U.S. payer system determine the highest-value exclusivity and launch dynamics. International bromfenac products may exist under different brand names, regulatory approvals, patent rights, and reimbursement systems.
Geographic value is therefore not uniform:
| Region |
Commercial implication |
| United States |
Core value market; strongest relevance of NDA, Orange Book, and Paragraph IV risk |
| Europe |
National reimbursement and country-specific approvals limit direct extrapolation from U.S. sales |
| Canada |
Smaller market with separate regulatory and reimbursement dynamics |
| Emerging markets |
Greater price sensitivity and potential local generic competition |
What is the investment outlook for PROLENSA?
PROLENSA should be valued as a cash-generating mature brand with limited standalone growth potential.
The upside case depends on:
- Continued growth in cataract procedures.
- Stable branded formulary access.
- Limited direct generic penetration.
- Successful retention of once-daily prescribing.
- Efficient manufacturing and distribution.
- Cross-selling through Bausch + Lomb’s surgical business.
The downside case depends on:
- Direct generic bromfenac 0.07% entry.
- Aggressive payer substitution.
- Lower net pricing.
- Reduced branded postoperative prescribing.
- Compounded or intraoperative alternatives.
- Product-quality or supply disruptions.
Because Bausch + Lomb does not disclose PROLENSA revenue, a defensible valuation should use scenario analysis rather than a claimed product-level sales forecast.
Key Takeaways
- PROLENSA is a mature Bausch + Lomb ophthalmic NSAID approved in 2013 for cataract-surgery inflammation and pain.
- Its commercial differentiator is once-daily bromfenac 0.07% dosing.
- The product benefits from durable cataract-procedure demand but faces intense generic and therapeutic substitution.
- FDA NCE exclusivity expired in 2018 based on the 2013 approval date.
- Current value depends on remaining formulation, method-of-use, and dosing protection, not on the bromfenac molecule itself.
- Bausch + Lomb does not separately report PROLENSA revenue, so product-level financial performance cannot be verified from public filings.
- PROLENSA has no biosimilar risk because it is a small-molecule ophthalmic drug.
- The most important downside event is direct generic bromfenac 0.07% entry, particularly if several manufacturers launch.
- The asset’s patent position is best assessed as moderate, with commercial durability driven as much by surgeon habits, payer access, and manufacturing quality as by patents.
FAQs
Is PROLENSA still a profitable drug?
It can remain profitable as a mature branded product, but public filings do not disclose its standalone revenue or profit. Profitability depends on branded pricing, payer access, manufacturing cost, and direct generic competition.
Is bromfenac the same as PROLENSA?
Bromfenac is the active ingredient. PROLENSA is Bausch + Lomb’s branded bromfenac sodium ophthalmic solution 0.07%.
Can a generic replace PROLENSA?
A generic bromfenac ophthalmic product can compete directly if it receives FDA approval and obtains market access. Generic ketorolac, diclofenac, and nepafenac products can also substitute therapeutically.
Does PROLENSA have biosimilar competition?
No. PROLENSA is a small-molecule ophthalmic drug and competes through the generic-drug pathway, not the biosimilar pathway.
What is the main commercial risk to PROLENSA?
The main risk is loss of branded volume and net price after direct generic bromfenac entry or broader payer substitution toward lower-cost ophthalmic NSAIDs.
References
-
Bausch + Lomb Corporation. (2024). 2023 annual report. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2013). PROLENSA prescribing information and approval materials for NDA 204091. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: PROLENSA, NDA 204091. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Valeant Pharmaceuticals International, Inc. (2012). Valeant Pharmaceuticals to acquire ISTA Pharmaceuticals. Company transaction announcement.
-
American Academy of Ophthalmology. (2023). Cataract in the adult eye preferred practice pattern. https://www.aao.org/education/preferred-practice-pattern/cataract-in-the-adult-eye-ppp-2021-disclaimer-2nd ed.
